Rani Therapeutics Holdings (Rani Therapeutics Holdings) Change In Receivables : $0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Rani Therapeutics Holdings Change In Receivables?

Rani Therapeutics Holdings's change in receivables for the quarter that ended in Dec. 2023 was $0.00 Mil. It means Rani Therapeutics Holdings's Accounts Receivable stayed the same from Sep. 2023 to Dec. 2023 .

Rani Therapeutics Holdings's change in receivables for the fiscal year that ended in Dec. 2023 was $0.00 Mil. It means Rani Therapeutics Holdings's Accounts Receivable stayed the same from Dec. 2022 to Dec. 2023 .

Rani Therapeutics Holdings's Accounts Receivable for the quarter that ended in Dec. 2023 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Rani Therapeutics Holdings's liquidation value for the three months ended in Dec. 2023 was $16.07 Mil.

Rani Therapeutics Holdings Change In Receivables Historical Data

The historical data trend for Rani Therapeutics Holdings's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rani Therapeutics Holdings Change In Receivables Chart

Rani Therapeutics Holdings Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Rani Therapeutics Holdings Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Receivables	Get a 7-Day Free Trial												-	-	-	-	-

Rani Therapeutics Holdings Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Rani Therapeutics Holdings (NAS:RANI) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Rani Therapeutics Holdings's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Rani Therapeutics Holdings's accounts receivable are only considered to be worth 75% of book value:

Rani Therapeutics Holdings's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	48.539	-	32.473	+	0.75 * 0	+	0.5 * 0
=	16.07

Rani Therapeutics Holdings Change In Receivables Related Terms

Thank you for viewing the detailed overview of Rani Therapeutics Holdings's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Rani Therapeutics Holdings (Rani Therapeutics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rani Therapeutics Holdings Inc (NAS:RANI) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

2051 Ringwood Avenue, San Jose, CA, USA, 95131

Website

https://www.ranitherapeutics.com

Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics. The company has developed the RaniPill capsule, a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing.

Executives

Talat Imran	director, officer: CEO	C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVENUE, SAN JOSE CA 95131
South Cone Investments Limited Partnership	10 percent owner	AVENIDA PRESIDENTE RIESCO 5711 OFICINA 1, LAS CONDES, SANTIAGO F3 7550000
Quiroga Cortes Isidoro Alfonso	10 percent owner	9020 N CAPITAL OF TEXAS HWY, SUITE I-260, AUSTIN TX 78759
Jean Luc Butel	director	ONE BAXTER PARKWAY, DEERFIELD IL 60015
Maulik Nanavaty	director	BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Kate Mckinley	officer: CHIEF BUSINESS OFFICER	C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVE., SAN JOSE CA 95131
Svai S Sanford	officer: CFO	C/O RANI THERAPEUTICS LLC, 2051 RINGWOOD AVE., SAN JOSE CA 95131
Eric Groen	officer: General Counsel	C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVE., SAN JOSE CA 95131
Mir Hashim	officer: Chief Scientific Officer	C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVENUE, SAN JOSE CA 95131
South Lake One Llc	10 percent owner	250 WEST 55TH STREET, NEW YORK NY 10019
Aequanimitas Limited Partnership	10 percent owner	LEONEL AGUIRRE 1830, UNIT 101, MONTEVIDEO X3 11500
Mir A Imran	director
Andrew Farquharson	director	C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVENUE, SAN JOSE CA 95131
Laureen Debuono	director
Lisa Ann Rometty	director	C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVE., SAN JOSE CA 95131